NCT05633654

Gilead GS-US-595-6184 ASCENT

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer that have Residual Disease After Surgery and Neoadjuvant Therapy

NCT06369285

Puma Biotechnology PUMA-ALI-1201

A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06790693

Genentech WO45654 INAVO123

A Phase III, Randomized, Open-Label Study of Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant both Combined with a CDK 4/6 Inhibitor, In patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

NCT06065748

Genentech CO44657 pionERA

A Phase III, Randomized, Open-Label Study of Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant both Combined with a CDK 4/6 Inhibitor, In patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

NCT05296798

Genentech WO43571 heredERA

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo After Induction Therapy With Phesgo+Taxane in Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive **ENROLLMENT ON HOLD

NCT06252649

Amgen 20210081 CodeBreaK301

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With our Without Bevacizumab-awwb for Treatment-na·ive Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT07176650

Shanhai Henlius HLX13-HCC102

A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase I Clinical Study to Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity of Ipilimumab Biosimilar HLX13 vs. YERVOY ® (US-Sourced YERVOY ®) As A First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

NCT06428019

AbbVie M24-287 VENETIAN

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated CLL **ENROLLMENT ON HOLD

NCT05254743

Loxo Oncology LOXO-BTK-20030

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) vs Ibruitinib in Patients with Chronic Clymphocytic Leukemia/Small Lymphocytic Leukemia (BRUIN-CLL-314)

NCT06973187

BeOne BGB-16673-304

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05211895

AstraZeneca D9075C00001 PACIFIC-8

A Phase Ill, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB1 54) in Participants with Locally Advanced (Stage Ill), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

NCT06350097

AstraZeneca D516NC00001 TROPION-LUNG14

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT07005128

Amgen 20240178

A randomized, open-label, multicenter, phase 3 study that will evaluate the efficacy and safety of tarlatamab in combination with the programmed cell death ligand-1 (PD-L1) checkpoint inhibitor durvalumab, carboplatin, and etoposide compared to the combination of durvalumab, carboplatin and etoposide in the treatment of individuals with untreated extensive stage small cell lung cancer (ES-SCLC)

NCT04613596

Mirati 849-007 KRYSTAL-7

"A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation ••open for Phase Ill (TPS ≥ 50%)"

NCT06767514

Summit SMT112-3007 HARMONi-7

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 (HARMONi-7)

NCT07155187

AbbVie M25-713 AndroMETa Lung 713

A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizetecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI (AndroMETa-Lung-713)

NCT06568939

AbbVie M25-274 AndroMETa Lung 536

A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06472245

OSE Immunotherapeutics OSE2101C302 ARTEMIA

A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study **Prescreen consent for HLA-A2 testing - consider prior to PD

NCT07222566

Pfizer C6461001

An Interventional Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination with Chemotherapy Versus Pembrolizumab in Combination with Chemotherapy in Adults Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06875310

BMS CA239-0004

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06417814

AstraZeneca D516KC00001 TROPION-LUNG15

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

NCT06207032

Tempus TP-CA-007 ARIES

A Biobank Registry Platform Study in Oncology

NCT05952024

AstraZeneca D8227C00002 ACRUE

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

NCT06158841

AbbVie M22-574 CERVINO

A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

NCT05939414

Novartis CAAA617D12302 PSMA-DC

An International, Prospective, Open-label, Multi-center, Randomized, Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)

NCT05803941

Novartis CAAA617A12402

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer